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1. Introduction 
Glioblastoma is the most common and aggressive type of primary brain tumor in humans. It 
is located preferentially in the cerebral hemispheres. Glioblastoma arises from complex 
interactions between a variety of genetic, epigenetic alterations and environmental 
perturbations. However, the precise mechanism of glioblastoma is unknown and its survival 
rate is very low. The Cancer Genome Atlas (TCGA) generates large-scale multi-dimensional 
genetic and epigenetic data to catalogue and identify cancer causing alterations (Kuhn, et al., 
2008). Glioblastoma (GBM) is the first cancer studied by TCGA. In TCGA glioblastoma pilot 
project, a total of 601 genes were sequenced for detection of somatic mutations in 179 tumor 
and matched normal tissues pairs; expressions of 12,042 genes were measured in 243 tumor 
tissue samples and 10 normal tissue samples and 1 cell line; expressions of 534 miRNAs 
were profiled in 240 tumor tissue samples and 10 normal tissue samples and a total of 2,994 
genes were examined for methylation in 239 tumor tissue samples and 1 cell line. This 
dataset will be used as an example for developing system biology and network approach as 
a general framework for integrated analysis of genetic and epigenetic alternations in cancer 
studies.  
Biological functions and mechanisms are encoded in network properties. An important 
strategy for unraveling the mechanisms of initiation and progression of cancer is to conduct 
analysis of complex genetic and epigenetic networks and study their behaviors under 
genetic and epigenetic perturbations. Robustness of a biological network, ability to retain 
much of its functionality in the face of perturbation (Dartnell, et al., 2005), has emerged as a 
fundamental concept in the study of network topological properties (Demetrius and Manke, 
2005 ). The locations of the DNA variants, mRNA, miRNA, and methylation in the genetic 
and epigenetic networks are likely to affect the phenotypes. We use network structural 
analysis as a tool to identify a set of key cancer causing genome alternations and core 
modules of biological networks that play an essential role in the development of cancer.  
Purpose of this report is to use system biology approaches to develop novel analytic 
strategies for systematically integrating genetic and epigenetic data. To achieve this, we 
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reconstruct genetic and epigenetic networks involved in tumorigenesis and study how these 
networks respond to perturbation such as somatic mutations and methylation. Information 
that defines the path from genomic variations to tumors flows from mutations and 
methylation through mRNA and miRNA expressions to tumor formation. Therefore, the 
components of complex genetic and epigenetic networks that determine cell function and 
response to perturbation of external stimuli include genes harboring DNA variations, 
mRNAs, miRNAs,  and methylation connected by their co-expressions or interactions. These 
networks consist of three levels. The subnetworks in the first level consist of mRNA and 
miRNA co-expression networks, mRNA and miRNA interaction networks. The 
subnetworks in the second level are miRNA target gene networks. The subnetworks in the 
third level are eQTL networks which connect mutations to gene and miRNA expression.  
Somatic mutations that are likely to cause tumorigenesis are traditionally identified by 
comparing differences in mutation frequencies between tumor and normal tissues 
individually. However, most somatic mutations are rare mutations. Due to their rarity, the 
frequencies of rare alleles may be compatible with sequencing errors. As a consequence, 
individual tests of association of rare variants with disease have little power and may not be 
robust. To overcome this limitation, we develop group association tests in which a group of 
rare genetic variants are jointly tested for assessing association of rare mutations and LOH 
with cancer. Multiple rare mutations, each with a minor marginal genetic effect, but 
collectively may make big contributions.  
We reconstructed two types of networks that connect mRNAs or miRNAs. One is mRNA or 
miRNA co-expression networks. To take inherent sparse structure of co-expression 
networks, we use partial correlation method and sparse regression techniques to infer co-
expression networks. Although co-expression networks are very useful for revealing 
transcriptional regulatory actions, they do not directly provide information on differences in 
regulatory effects between tumor and normal tissues. It is differences in regulatory effects 
that cause cancer. Therefore, we propose a new concept of a regulatory difference network 
that is formally referred to as mRNA or miRNA interaction networks. We detect interaction 
between mRNAs or miRNAs by measuring differences in their mutual information between 
tumor and normal tissues and develop a novel MI-based statistic to test interaction between 
two mRNAs or miRNAs.  
miRNAs are short endogenous noncoding RNAs of 22 nt that negatively regulate gene 
expression through base pairing with target mRNAs (Huang, et al., 2007; Huang, et al., 2007). 
It is increasingly recognized that miRNAs have emerged as an important component in the 
regulation of gene expression, with imperfect base pairing, to target sites in the 3’ UTR of 
messenger RNAs (Gennarino, et al., 2009). Three types of methods have been used to identify 
potential target genes: sequence analysis, miRNA-mRNA regression analysis, and machine 
learning (Huang, et al., 2007; Maziere and Enright, 2007; Yang, et al., 2008). Sequence analysis 
methods rely on knowledge of the base pairing between and second structure of the miRNA 
and the target gene. However, the sequence approach has limited specificity due to imperfect 
miRNA-target pairing (Huang, et al., 2007; Huang, et al., 2007). Regressing the expression of a 
target gene on the expression of miRNA for identifying miRNA target is based on a linear 
relationship between miRNA and its target mRNA. However, the relationship between 
miRNA and target mRNA may be nonlinear, which leads to inaccurate prediction of the 
miRNA target. The precision of miRNA target prediction by machine learning depends on the 
number of experimentally validated miRNA targets; however, the number of experimentally 
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validated targets is limited. To improve the accuracy of target prediction, we will combine 
sequence analysis with regression analysis for target prediction.  
2. Materials and methods 
2.1 Test association of somatic mutations and LOH with glioblastoma 
Cancers arise from mutations that confer growth advantage on cells (Greenman, et al., 
2007).The somatic mutations in cancers can be classified either as “drivers” or “passengers” 
(Wood, et al., 2007). As the number of tumor tissues and normal tissues increases we can 
observe somatic mutations in both tumor and normal tissues. The current popular method 
for identifying driver mutations is to compare the difference in the mutation rates (Kuhn, et 
al., 2008; Parsons, et al., 2008). However, there is debate about how to assess a significant 
excess of mutations in tumors (Rubin and Green, 2007). We need to develop formal tests to 
detect differences in mutation rates between tumor and normal tissues. Most traditional 
statistical methods that often test the association of genetic variants individually were 
designed for testing association of common alleles with common diseases and are 
inappropriate for testing the association of rare somatic mutations. A feasible approach is to 
record rare sequence variants at different genome positions and to collectively test 
association of a set of rare variants. It has been shown that the number of rare alleles in large 
samples is approximately distributed as a Poisson process with its intensity depending on 
the total mutation rate(Joyce and Tavare, 1995). The intensity of the Poisson process within a 
segment of genome can be interpreted as the mutation rate. Similar to standard 2 test for 
association of SNPs which compare the difference in allele frequencies between cases and 
controls, the proposed statistics are to compare difference in the mutation rates between 
tumor and normal samples. Specifically, letU andV be the average number of rare 
mutations which is the intensity of the Poisson process underlying the rare variants, in the 
tumor and normal samples, respectively. Let uvS be the pooled sample variance of the rare 
variants. Define the test statistic: 
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                               (1) 
where An and Gn  are the number of sampled tumor tissues and normal tissues, 
respectively. Under the null hypothesis of no association of the set of rare variants with the 
disease, the average number of rare alleles in cases and controls should be equal and the 
statistic GT is asymptotically distributed as a central
2
(1) distribution. In some cases, we may 
have a homozygous genotype of rare mutations. To improve the power, in this case, we can 
count it twice. Instead of defining statistics in terms of genotype, we can similarly define the 
test statistics in terms of the rare alleles, which is denoted as aT .   
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To examine the validity of the test statistics, we performed a series of simulation studies. We 
used infinitely many allele models and software (GENOME) to generate rare variants. 
Suppose that the mutation rate per generation per base pair is 81.00 10 , the recombination 
rate between consecutive fragments is 0.0001, the migration rate per generation per 
individual is 0.00025, we have simulated 100 fragments with the length of each fragment 
equals 10k in base pair. Total of 100,000 individuals who were equally divided into cases 
and controls were generated in the general population. 500 to 2,000 individuals were 
randomly sampled from each of the cases and controls. 10,000 simulations were repeated.   
Table 1 summarized the type I error rates of two statistics. Table 1 showed that the 
estimated type I error rates of the statistics for testing association of a set of rare variants 
with the disease were not appreciably different from the nominal levels 0.05,  0.01   
and 0.001  .   
A LOH mutation was recorded when the genotype in blood or normal tissue is 
heterozygous, and in the tumor tissue, the reference allele loses normal function and the 
genotype becomes homozygous. The statistic GT can be used to test association of LOH with 
glioblastoma.  
 
Sample Sizes  GT  aT  
2,000  =0.001 0.0012 0.001 
 =0.01 0.0093 0.0096 
 =0.05 0.0489 0.0494 
1,500  =0.001 0.0015 0.001 
 =0.01 0.0106 0.0092 
 =0.05 0.0521 0.0500 
1,000  =0.001 0.0012 0.0007 
 =0.01 0.0106 0.0097 
 =0.05 0.0522 0.0459 
500  =0.001 0.0009 0.0008 
 =0.01 0.0102 0.0117 
 =0.05 0.0504 0.0548 
Table 1. Type 1 error rates of the statistics ,G aT T . 
2.2 Lasso for co-expression networks 
A co-mRNA expression or co-miRNA expression network can be constructed by joint sparse 
regression for estimating the concentration matrix in which off-diagonal elements represents 
the covariance between the corresponding variables given all other variables in the network 
(Peng, et al., 2009 ) . Sparse regression for reconstruction of co-expression network is briefly 
introduced here. (For details, please see(Peng, et al., 2009 )). Denote the mRNA or miRNA 
expression levels as variables 1 ,... qy y . A variable is represented by a node. An edge 
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connecting two nodes indicates that the connected two variables are conditionally 
dependent, given all other variables. Assume that the vector of q variables 
1[ ,... ]
T
qY y y follow a normal distribution (0, )N  . Denote the partial correlations as 
( , )( , | )
ij
i j i jCorr y y y   for 1 i j q   and ( , ) { : 1 , }i j k k i j q     . If we assume the 
normality of the variables, then  two variables iy and jy are conditionally dependent, given 
all other variables if and only 0ij  . Let 1 ( )ij  be the concentration matrix. Then, 
  
ij
ij
jjii

 
    
                                                       
 (2) 
When sample size is much larger than the number of variables, the concentration matrix can 
be directly estimated from the inverse of the sampling covariance matrix. However, when 
the number of variables in the network is larger than the sample size, the inverse of 
sampling covariance matrix may not exist. We use sparse regression for network modeling 
via estimating sparse concentration matrix.  
2.3 Functional module identification and gene set enrichment analysis 
Co-expression networks are usually organized into functional modules that perform specific 
biological tasks. Genes within coexpression modules often share conserved biological 
functions. A dynamic tree cut procedure was used to identify modules(Langfelder, et al., 
2008). A co-expression network was clustered using hierarchical clustering. Modules are 
defined as braches of dendrogram. One sided Fisher exact test that calculates the probability 
of seeing observed number of genes within a pathway or a GO category in the module by 
chance was used to test for enrichment of a pathway or a GO category in the module. We 
assembled 465 pathways from KEGG(Hashimoto, et al., 2006) and Biocarta 
(http://www.biocarta.com).  
2.4 miRNA interaction and mRNA Interaction networks 
Modern complex theory assumes that the complexity is the degree to which components 
engage in organized structured interactions. Intuitively, complexity can also be viewed as 
the degree of dependence among components. Therefore, interaction has been considered as 
a sensible measure of complexity of biological systems. The more interactions between 
components, the more complex the system is. We identify mRNA or miRNA interaction 
networks via detecting pair-wise interaction between mRNAs or miRNAs. We view mRNA 
or miRNA expressions as continuous variables. Formally, interactions can generally be 
defined as a stochastic dependence between two random variables. The concept of mutual 
information proposed by Shannon(Cover and Thomas, 1991) can serve as a general measure 
of interaction (dependence) between two random variables(Jakulin, et al., 2003; Matsuda, 
2000; Nakahara, et al., 2003). It quantifies the stochastic dependence between two random 
variables. An additional asset is that mutual information measures more than linear 
dependence(Brillinger, 2004; McGill, 1954 ). Therefore, information theory will provide an 
unified framework for developing statistical methods to detect interaction between mRNAs 
or miRNAs. Similar to the detection of interaction between two SNPs where interaction 
between two SNPs is measured and tested as the difference in linkage disequilibrium(LD) 
between cases and controls(Wu, et al., 2008; Zhao, et al., 2006), we detect interaction 
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between mRNAs or miRNAs by measuring differences in mutual information between 
tumor and normal tissues.  
The expression of mRNAs and miRNAs are continuous variables. Usually, we assume that 
they follow a normal distribution. Let random variables X and Y denote the expression of a 
pair of mRNAs or miRNAs. Let ( ), ( )f x f y and ( , )f x y be the distribution functions of X and 
Y and their joint distribution function, respectively. The mutual information between two 
continuous variables is defined as  
 ( , )( , ) log
( ) ( )
f x y
I X Y E
f x f y
    
 
                   
(3) 
This formula shows(Cover and Thomas, 1991) that mutual information is always 
nonnegative and is equal to zero if and only if two random variables are independent. 
Therefore, mutual information can be used to measure the degree of stochastic dependence. 
Assuming the normal distribution of two random variables, mutual information can easily 
be calculated by  
 2
1
( , ) log(1 ),
2
I X Y     
                    
(4) 
where  is a canonical correlation. Similar to using LD to test interaction between two SNPs 
where tests for interaction between unlinked and linked loci are developed separately, we 
consider two cases in testing interaction between mRNAs or miRNAs: (1) a pair of mRNAs 
or miRNAs in the normal tissues are independent and (2) a pair of mRNAs or miRNAs in 
the normal tissues are dependent. 
2.4.1 A pair of mRNAs or miRNAs in the normal tissues is independent 
Let ( , )TI X Y and ( , )NI X Y be mutual information between 1x and 2x in tumor and normal 
tissues, respectively. Let An  and Gn  be the number of tumor and normal samples, 
respectively. Then, ˆ2 ( , )A Tn I X Y and 
ˆ2 ( , )G Nn I X Y are asymptotically distributed as a 
2
(1)  
distribution (Brillinger, 2004). Define the statistic: 
 ˆ ˆ2 ( , ) 2 ( , )I A T G NT n I X Y n I X Y   
                         
(5) 
It has been shown(Holm and Alouini, 2004) that under the null hypothesis of no interaction, 
IT  has a distribution with the following probability density function 
 
0
1
( ) ( )
2 2
x
f x K  
                  
(6) 
where 0( )K  is the modified Bessel function of the second kind of order 0 (Jeffrey and 
Zwillinger, 2000). 
2.4.2 A pair of mRNAs or miRNAs in the normal tissues is dependent 
When a pair of mRNAs or miRNAs in the normal tissues is dependent, we can define a test 
statistic that has a much simpler distribution than that of test statistic IT . Let ˆA and ˆG be 
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the canonical correlation in tumor and normal tissues, respectively. We propose a novel 
statistic defined as  
 
2
2
[ ( , ) ( , )]
ˆ(1 / 1 / )
T N
D
A G
I X Y I X Y
T
n n 
   
               
(7) 
where 2
1
ˆ( , ) log(1 )
2
T AI X Y     and 21 ˆ( , ) log(1 )
2
N GI X Y    . Then DT follows a central 
2
(1)  distribution under the null hypothesis of no difference in mutual information between 
tumor and normal tissues. To evaluate the validity of the test statistic DT , we calculated its 
type 1 error rates. We simulated a population of size 1,000,000 from a bivariate normal 
distribution with mean[0,0]T . Then, we equally sampled 100, 200 and 400 subjects as tumor 
and normal samples and calculated the test statistic DT . We repeated this with 10,000 
simulations. The type 1 error rates for different samples and correlation coefficients were 
listed in Table 2. Type I error rates for the statistics DT to test for the interactions between 
two mRNAs or miRNAs were not appreciably different from the nominal levels 0.05  , 
0.01   and 0.001  .   
 
  Sample 
Sizes 
Nominal Level 
0.001   0.01   0.05   
0.2 100 0.0023 0.0113 0.0552 
 200 0.0010 0.0086 0.0494 
 400 0.0011 0.0115 0.0529 
0.5 100 0.0008 0.0103 0.0532 
 200 0.0011 0.0108 0.0528 
 400 0.0012 0.0104 0.0496 
Table 2. Type 1 error rates of DT for testing interaction between two continuous variables 
2.5 Ranking of the nodes in the network 
Biological functions and mechanisms are encoded in network properties. An important 
strategy for unraveling the mechanisms of initiation and progression of cancer is to conduct 
analysis of complex biological networks and study their behaviors under genetic and 
epigenetic perturbations. Robustness of a biological network, ability to retain much of its 
functionality in the face of perturbation(Dartnell, et al., 2005), has emerged as a fundamental 
concept in the study of network topological properties(Demetrius and Manke, 2005 ). 
Widely used measures of network robustness include ranking importance of the nodes in 
the network. One of the most efficient measures of importance in robustness analysis of the 
network is the damage value of a node which quantifies the effect of the removal of that 
particular node from the network. Formally, we define the damage value of a node as 
follows. Let ( , )G V E be the connected component that contains node h V , and 
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let ( , )G V E   be the largest connected component of G , after the removal of node h . Then, 
the value ( ) | | | |D h V V   is the damage value of node h .  
2.6 Identify the genetic variants that have cis or trans regulatory effects on miRNA or 
mRNA expressions 
Loci that are significantly associated with expression are called expression quantitative trait 
loci (eQTL). Somatic mutations may directly or indirectly regulate the expression of mRNAs 
or miRNAs. The traditional statistical methods to regress the expression levels on the 
individual genetic variant for identifying eQTL is inappropriate for studying the regulatory 
effect of somatic mutations due to their low allele frequencies. An alternative approach to 
current variant-by-variant regression method is groupwise regression methods in which a 
group of rare genetic variants are jointly analyzed. It is well known that eQTL include cis-
eQTL in which an association exists between the expression of a specific gene (mRNA) and 
the genetic variants at that gene’s locus, or between the expression of miRNA and the 
genetic variants at its host gene, and trans-eQTL in which there is an association between the 
expression of a gene or a miRNA and the genetic variants at a non-local genomic locus.  
Regression methods that regress the expression of a mRNA or a miRNA on the number of 
all mutated alleles across the region of interest to identify cis- or trans-eQTL . 
2.7 miRNA target networks 
miRNAs down regulate gene expressions by base-pairing with  the 3’-noncoding region of 
the target mRNAs. It is estimated that up to 30% of genes might be regulated by 
miRNAs(Sassen, et al., 2008). It is hypothesized that miRNAs and their targets form 
complex networks to perform various biological functions. To reveal mechanisms of the 
GBM, we identified target genes of miRNAs and constructed miRNA target networks. 
Procedures for discovering the target genes consisted of two steps. The first step was to 
conduct sequence analysis that used sequence complementarities of miRNA and its target 
site to predict potential miRNA target genes. We searched the predicted potential miRNA 
targets in  miRGen(Megraw, et al., 2007), which integrated animal miRNA targets according 
to combinations of four widely used target prediction programs: miRanda, PicTar, 
TargetScan, DIANA-microT, and experimentally supported targets from TarBase 
(Sethupathy, et al., 2006) and miR2Disease(Jiang, et al., 2009). Since miRNAs repress the 
expression of their target genes, the second step was to test the inverse relationship between 
the expression profile of miRNA and that of its potential targets. To achieve this,   we 
regressed the expression of target mRNAs on the expression of miRNAs and select mRNAs 
with significant negative regression coefficients as miRNA targets. P-value for declaring 
significant evidence of miRNA target was 41.00 10 .  
3. Results 
3.1 Test association of somatic mutations and LOH mutations with glioblastoma 
The first step for deciphering the path from somatic mutations to the GBM is to test 
association of somatic mutations with the GBM. The statistic aT  and GT  was applied to 
glioblastoma in TCGA dataset. The tumor tissues of 179 glioblastoma patients and 179 
matched normal tissues were sequenced. A somatic mutation was recorded when the 
mutation was detected only in the tumor tissue. There were 306 genes in which at least one 
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somatic mutation was detected. A LOH mutation was recorded when the genotype in blood 
or normal tissue is heterozygous, and in the tumor tissue, the reference allele loses normal 
function and the genotype becomes homozygous. There were 124 genes in which at least 
one LOH mutation was detected. We identified association of somatic mutations in 14 genes 
by the statistics aT (Table 3), and association of LOH in 11 genes by the statistic GT with 
glioblastoma with false discovery rate (FDR) less than 0.05 (Table 4). Genes TP53, PTEN, 
EGFR, NF1, RB1 and ERBB2 were reported to be associated with GBM in the previous 
TCGA data analysis (The Cancer Genome Atlas Research Network, 2008). The remaining 8 
somatic mutated genes and 10 LOH mutated genes were newly identified by the 
statistics GT or aT . NCBI Entrez gene database (Maglott, et al., 2007) reported that : CHEK2 is 
  
Gene P-value FDR Mutation frequency 
TP53 3.46E-11 5.90E-10 0.1453 
PTEN 2.25E-07 1.92E-06 0.0698 
EGFR 1.22E-06 6.92E-06 0.0587 
FKBP9 1.38E-04 5.89E-04 0.0363 
CHEK2 1.39E-03 4.73E-03 0.0475 
GSTM5 2.41E-03 6.86E-03 0.0251 
DST 4.28E-03 8.12E-03 0.0223 
RB1 3.54E-03 8.62E-03 0.0251 
NF1 4.17E-03 8.89E-03 0.0363 
BCL11A 1.36E-02 2.33E-02 0.0168 
ERBB2 1.57E-02 2.43E-02 0.0307 
PIK3C2G 2.45E-02 3.49E-02 0.0140 
FN1 3.30E-02 4.33E-02 0.0168 
COL3A1 4.46E-02 4.75E-02 0.0112 
Table 3. P-values for testing association of somatic mutations with the GBM 
 
Gene P-value FDR Mutation frequency 
NRAP 5.71E-07 6.24E-06 0.1173 
MKI67 8.19E-07 4.47E-06 0.1229 
C10orf54 1.02E-04 3.70E-04 0.0391 
C9orf66 1.63E-04 4.46E-04 0.0419 
MYO3A 6.40E-04 1.40E-03 0.0307 
PRAME 2.14E-03 3.90E-03 0.0251 
EGFR 3.20E-03 4.99E-03 0.0279 
IL1RL1 7.11E-03 9.71E-03 0.0196 
HLA-DOA 1.30E-02 1.57E-02 0.0168 
ABCA13 2.37E-02 2.59E-02 0.0140 
CYP1B1 2.37E-02 2.59E-02 0.0140 
Table 4. P-values for testing association of LOH with the GBM 
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a cell cycle checkpoint regulator and putative tumor suppressor, and associated with GBM; 
GSTM5 was reported to be involved in cancer, BCL11A is a proto-oncogene, and FN1 is 
involved in tumor metastasis and angiogenesis. Gene PRAME was reported to be associated 
with melanoma and acute leukemias.  Association of the other 9 genes such as NRAP, 
MK167, C10orf54 and C9orf66 with GBM was first reported here 
3.2 Network analysis of gene expressions  
3.2.1 Differential expression analysis 
Comparative studies of gene expression between normal and tumor tissues is one of the 
most widely used strategies for unraveling the molecular circuitry underlying cancer (Liang 
and Pardee, 2003). To uncover the mechanisms of glioblastoma, expressions of 12,042 genes 
were measured in 243 tumor tissue samples and 10 normal tissue samples and 1 cell line by 
Affymetrix HT Human Genome U133 Array Plate Set. A total of 1,697 genes were 
differentially expressed between tumor and normal tissues by Wilcoxon rank-sum test (P-
value for declaring significance after Bonferroni correction is 64.15 10 ). Of the 1,697 genes, 
72 genes were  cancer genes or cancer candidate genes, 25 of which were GBM related genes 
including TCF12, TP53, COL4A1, COL3A1 and COL5A2, 11 of them were oncogenes 
including CDK4 and RAF4; 21 of them were tumor suppressor genes including TP53 and 
RB1 (We got the oncogene and tumor suppressor gene list from database: TSGDB(Yang and 
Fu, 2003) and UNSW Embryology DNA Tumor Suppressor and Oncogene 
Database(Ackermann and Strimmer, 2009)), 242 genes were in signal transduction 
pathways, 908 genes were down regulated and 789 genes were up regulated. From 1,697 
significantly differentially expressed genes, we identified 97 genes that were reported to be 
cancer related in the literatures (Table 5).  
 
Gene P-value Up-down Cancer Gene TSG Cancer Signaling 
ICAM5 2.52E-08 Down CAN-gene
TCF12 2.84E-08 Up Cancer Gene regulation 
THRB 3.2E-08 Down oncogene
ABR 3.2E-08 Down TSG
BTG1 3.28E-08 Up Cancer Gene TSG
KIAA0774 3.97E-08 Down CAN-gene
TMEM123 3.97E-08 Up CAN-gene
IGFBP7 4.57E-08 Up TSG
MAP2K4 4.68E-08 Down Cancer Gene TSG Kinase 
ELK1 4.68E-08 Down oncogene TF
COL4A1 4.91E-08 Up GBM
CD93 5.14E-08 Up CAN-gene
CDK2AP1 6.21E-08 Up TSG
ITGAV 7.49E-08 Up GBM
EDIL3 8.81E-08 Down GBM
RB1 1.24E-07 Up Cancer Gene TSG TF
GRM1 1.33E-07 Down CAN-gene
TP53 1.40E-07 Up Cancer Gene TSG TF
CDH11 1.46E-07 Up Cancer Gene
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Gene P-value Up-down Cancer Gene TSG Cancer Signaling 
CDKN2C 1.49E-07 Up GBM CDK inhibitors 
SNAP25 1.53E-07 Down GBM Vesicle 
LDOC1 1.67E-07 Down TSG
IGFBP2 1.67E-07 Up GBM
BCL11B 1.75E-07 Down Cancer Gene
FABP3 1.77E-07 Down   TSG   
RARG 1.88E-07 Down GBM
PTPN13 2.3E-07 Up TSG cytoskeleton 
GABRB2 2.40E-07 Down GBM
EIF4A2 2.46E-07 Down Cancer Gene
SP110 2.69E-07 Up CAN-gene
GAS1 2.75E-07 Up TSG
RIMS2 3.59E-07 Down CAN-gene
VSNL1 3.83E-07 Down GBM Adapter 
CDH12 4.01E-07 Down Cancer Gene
RAP1GDS1 4.38E-07 Down CAN-gene
LMO7 4.57E-07 Down CAN-gene
ATM 4.99E-07 Up Cancer Gene TSG Kinase 
PDE4DIP 5.21E-07 Down Cancer Gene
HIP1 5.69E-07 Up Cancer Gene cytoskeleton 
PRPF4B 5.94E-07 Up CAN-gene
NUP214 6.34E-07 Up Cancer Gene Transporter 
HSP90AB1 6.77E-07 Down Cancer Gene
LYN 7.07E-07 Up oncogene Kinase 
COL5A2 7.54E-07 Up GBM
BCL10 8.04E-07 Up Cancer Gene apoptosis 
NCKIPSD 8.04E-07 Down Cancer Gene
TRIM24 8.40E-07 Up Cancer Gene
CLTC 8.95E-07 Down Cancer Gene SP
RAF1 9.55E-07 Up oncogene Kinase 
SYK 1.02E-06 Up Cancer Gene Kinase 
PIM1 1.03E-06 Up Cancer Gene oncogene
SYT1 1.04E-06 Down CAN-gene Vesicle 
MAPK8IP2 1.08E-06 Down CAN-gene
CHI3L2 1.13E-06 Up GBM
YES1 1.21E-06 Up oncogene Kinase 
ATP8A2 1.31E-06 Down TSG Molecule 
GABRA1 1.31E-06 Down GBM Receptor 
RASSF1 1.34E-06 Up TSG
CHIC2 1.43E-06 Up CAN-gene
MYT1L 1.55E-06 Down GBM
COL3A1 1.55E-06 Up GBM
NBL1 1.62E-06 Down TSG
NONO 1.80E-06 Up Cancer Gene
TPR 1.80E-06 Up Cancer Gene
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Gene P-value Up-down Cancer Gene TSG Cancer Signaling 
NOV 1.87E-06 Down oncogene GF
CDK4 1.87E-06 Up GBM oncogene Kinase 
TCF3 1.95E-06 Up Cancer Gene TF
NEFM 1.95E-06 Down GBM Cytoskeleton 
SYN2 2.08E-06 Down GBM
FLT3 2.17E-06 Down Cancer Gene   Generics 
CCK 2.17E-06 Down GBM
IDH1 2.26E-06 Up GBM
CDC23 2.31E-06 Up TSG
CHI3L1 2.31E-06 Up GBM
BCL6 2.35E-06 Up Cancer Gene
RTN1 2.40E-06 Down GBM
DLEU2 2.43E-06 Up TSG
SH3GL2 2.50E-06 Down GBM Vesicle 
BLM 2.56E-06 Up Cancer Gene
SMAD4 2.56E-06 Up Cancer Gene TF
CACNA2D2 2.95E-06 Down TSG
PRRX1 2.95E-06 Up Cancer Gene
SV2B 2.95E-06 Down GBM
NEFL 3.01E-06 Down GBM
MCF2 3.14E-06 Down oncogene Cytoskeleton 
CTNNA1 3.14E-06 Up TSG Cytoskeleton 
BMPR1A 3.27E-06 Up Cancer Gene Receptor 
MSN 3.40E-06 Up Cancer Gene
RPN1 3.54E-06 Up Cancer Gene
LPP 3.69E-06 Up Cancer Gene
GABRG2 3.77E-06 Down GBM
TRIM8 3.77E-06 Down TSG 
COX6C 3.84E-06 Down Cancer Gene
FBXW7 4.00E-06 Down Cancer Gene Generics 
ETS2 4.34E-06 Down oncogene TF
EWSR1 4.8E-06 Up oncogene
ST5 4.99E-06 Up TSG 
*TSG:  tumor suppressor gene; TF: transcription factor; SP: Structural Protein,  GF: Growth Factor 
Table 5. A list of 97 genes was differentially expressed. 
3.2.2 Gene co-expression network analysis 
To investigate the functions of the genes at the system-level and uncover the mechanism of 
GBM, we used partial correlation method and sparse regression techniques to infer gene co-
expression networks. The largest connected coexpression network with the average shortest 
path 20.4 and diameter 74 had 2,115 genes and 2,276 edges (Figure 1).  
To explore the relationship between co-expressions of the genes and physical interaction 
between their corresponding proteins, we compared the constructed co-expression gene 
network with the protein-protein interaction (PPI) network (Chuang, et al., 2007), 
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comprising 57, 235 interactions among 11, 203 proteins. The human PPI network was 
integrated from yeast two-hybrid experiments, predicted interactions based on orthology 
and co-citation, and curation of literature. We restricted our analysis to 3,991 genes present 
in both co-expression and PPI networks, consisting of 2, 131 and 12, 182 edges, respectively. 
The two networks shared 85 edges involving 133 genes in common. The 133 genes and their 
connections were shown in Figure 2. We performed functional enrichment analysis of the 
133 genes using DAVID(Huang da, et al., 2009). Enriched gene functional categories include 
protein biosynthesis/ribosome, development processes, metabolic processes and RNA 
splicing. It is noticeable that the largest connected component, which consists of 29 genes, in 
Figure 2 corresponds to a ribosomal protein complex. 
 
 
 
Fig. 1. The largest connected gene co-expression network. The network had 2,115 genes and 
2,276 edges. Genes related to GBM were highlighted in red. 
The network had 133 genes and 700 edges. This figure gives the sub-network of gene co-
expressions in which a node contains both gene co-expressions and protein-protein 
interactions with other nodes in this sub-network. 
Co-expression networks are usually organized into modules that perform specific biological 
process. 13 modules were significantly enriched for at least one pathway(Figure 3 and Table 
6), indicating that co-expression network was organized into functional units. Enriched 
pathways in the modules were involved in neurodegenerative diseases, development 
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processes, cancer related signaling pathways and metabolism. Parkinson’s disease pathway 
was enriched in module 11 with olive green color. Genes UQCRC1, ATP5H, COX7C, 
NDUFA1, COX5R and COX4I1 in the module 11 are involved in mitochondria dysfunction 
(http://www.genome.jp/kegg/pathway/hsa/hsa05012.html). Cell cycle pathway was 
enriched in module 7 with yellow color. We can see that co-expressed genes CHEK2, 
CCNB2, CCNA2, CCNE2, MAD2L1 and BUB1 in module 7 are directly or indirectly 
connected in cell cycle pathway (http://www.genome.jp/dbget-bin /show_ pathway? 
hsa04110).   
 
 
 
 
 
 
Fig. 2. Gene co-expressions and interactions supported by protein-protein interactions.  
The architecture of a co-expression network is important for uncovering the genes which are 
involved in cancer. To identify the most important genes in the co-expression network, we 
used the damage value of a node as a measure to rank the importance of a node. We ranked 
all differentially expressed genes in the largest co-expression sub-network according to their 
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damage values. Top 5% genes in the ranked list with the damage values greater than 15 
were summarized. These genes were essential to the function of co-expression network. We 
suspect that these genes may be involved in the development of GBM. For example, T1A1 
that had the largest damage value 38 and was over expressed in the GBM tissues plays a 
role in apoptosis (Forch and Valcarcel, 2001). KIAA1279 was reported to be associated with 
the nervous systems (Brooks, et al., 2005). It was also reported that CACYBP participates in 
p53-induced beta-catenin degradation and can suppress proliferation and tumorigenesis of 
renal cancer cells (Sun, et al., 2007). CACYBP was under expressed in gastric cancer (Ning, 
et al., 2007) and renal cancer (Sun, et al., 2007). 
 
 
Fig. 3. 13 functional modules in the largest connected gene-coexpression network in Figure 
1. The modules were indexed by the number and also represented by color. Enriched 
pathways in the modules were listed in Table 6.  
There were three genes: TP53, COL3A1, and RAP1GDS1 whose damage values ranked the 
top among the cancer and cancer candidate genes (Table 5). Their removal from the network 
may disconnect some components in the network and hence compromise the functions of 
the genes in coexpression networks. TP53 and COL3A1 are GBM related genes and 
RAP1GDS1 is a cancer candidate gene. The p53 pathway is central to oncogenesis (El 
Hallani, et al., 2009). TP53, which was up regulated in GBM tissue samples, particularly, was 
highly over-expressed in CEREBRUM tissue samples. It was observed that TP53 had 
damage value 23, but was only connected with two up regulated genes: TGIF2 and EIF4A1. 
TGIF2 was differentially expressed (P-value< 71.43 10 ) and had damage value 24. TGIF2 is 
a novel TALE superclass homeodomain protein and a transcriptional co-repressor that 
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interacts with Smad2 and Smad3 to negatively regulate the TGFb/Smad response in a cell, 
which in turn affects apoptosis and leads to cellular proliferation and differentiation. TGIF2 
plays an oncogenic role through inhibition of TGFb (Imoto, et al., 2000).  EIF4A1 was over 
expressed in tumor tissue (P-value< 65.09 10 ) and had damage value 22. EIF4A1 is ATP-
dependent RNA helicase and required for mRNA binding to ribosome. EIF4A1 inhibit 
translation initiation and act as a tumor suppressor by forming complex with Programmed 
Cell Death 4 (PDCD4) (Yang, et al., 2004). COL3A1 was over expressed in GBM tissue 
samples (P-value< 61.6 10 ) and had damage value 21. It was also reported to be over  
 
# color Category Name P-value 
1 Purple Cell Signaling 
Ion Channel and Phorbal Esters 
Signaling 
8.60E-03 
2 
Wind-
Stawberry 
Apoptosis 
Apoptotic DNA fragmentation and 
tissue homeostasis 
3.52E-02 
Cell Cycle 
Regulation 
Activation of Src by Protein-
tyrosine phosphatase alpha 
4.23E-02 
Cell Cycle 
Regulation 
AKAP95 role in mitosis and 
chromosome dynamics 
4.98E-02 
Cell Cycle 
Regulation 
Sonic Hedgehog (SHH) Receptor 
Ptc1 Regulates cell cycle 
4.23E-02 
3 
Forest-
Green 
Translation Ribosome 3.32E-09 
4 TealBlue 
Metabolism of 
Cofactors& 
Vitamins 
One carbon pool by folate 4.72E-02 
5 Black Cell Signaling 
Ca++/ Calmodulin-dependent 
Protein Kinase Activation 
3.59E-03 
6 
Green-
Yellow 
Immunology 
Cells and Molecules involved in 
local acute inflammatory response 
4.68E-02 
7 Yellow 
Cell Growth and 
Death 
Cell cycle 2.62E-02 
8 Orange Immunology Classical Complement 2.85E-02 
9 Lavender Cell Signaling IFN alpha signaling 1.03E-02 
10 Blue Cell Activation Th1/Th2 Differentiation 3.79E-02 
11 OliveGreen
Metabolism 
Electron Transport Reaction in 
Mitochondria 
1.31E-02 
Energy 
Metabolism 
Oxidative phosphorylation 9.00E-03 
Neurodegene-
rative Diseases 
Parkinson's disease 8.67E-03 
12 Maroon Translation Ribosome 1.13E-03 
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# color Category Name P-value 
13 Red 
Metabolism| 
Neuroscience 
Vitamin C in the Brain 9.11E-03 
Cell Activation 
Angiotensin-converting enzyme 2 
regulates heart function 
1.27E-02 
Metabolism Intrinsic Prothrombin Activation 3.83E-02 
Metabolism Platelet Amyloid Precursor Protein 1.47E-02 
Hematopoiesis Regulators of Bone Mineralization 2.58E-03 
Table 6. 13 Modules in gene co-expression network in Figure 3 with their enriched 
pathways. 
expressed in ovarian cancer and breast cancer (Helleman, et al., 2006; Turashvili, et al., 
2007). COL3A1 encodes a fibrillar collagen which is a major component of the extracellular 
matrix protein surrounding cancer cells. Presence of ECM protein prevents apoptosis of 
cancer cells. COL3A1 plays an important role in apoptosis, proliferation regulation and 
anticancer drug resistance (Sethi, et al., 1999). RAP1GDS1 was under expressed in GBM 
tissue samples (P-value < 4.4 710 ) and had damage value 18 in the co-expression network. 
RAP1GDS1 is a transcription factor (Cimino, et al., 2001). It was reported that translocation 
fusion of the NUP98 and RAP1GDS1 genes was recurrent in T-cell acute lymphocytic 
leukemia (Hussey, et al., 1999). 
3.2.3 Gene interaction network analysis 
To further uncover the mechanism of the GBM, the proposed MI-based statistic was applied 
to expressions of 12,042 genes which were measured in 243 tumor tissue samples and 10 
normal tissue samples and 1 cell line to detect pair-wise mRNA interaction between the 
genes. We detected 967 interaction with theoretic P-values< 151.0 10 accounting for 0.1% 
proportion of total interactions. Pair-wise mRNA interactions were assembled into 
interaction networks defined by representing genes as nodes, with an edge between two 
nodes if an interaction was observed between the corresponding genes. The resulting largest 
connected mRNA interaction network consists of 187 genes and 196 edges (Figure 4) . Its 
average shortest path length was 5.88 and diameter was 23.  
Top 10 genes with the largest damage value were SIVA1, SLC27A5, PFDN5, GBAS, 
COX6A1, AKR1B1, NPM3, UBE2W, CDK4 and SGCG. The gene with both the largest degree 
(32) and damage value (62) in the mRNA interaction network was SIVA1, an apoptosis-
inducing factor. SIVA1 was over expressed in the GBM tissue samples (P-value < 0.00061). 
Although it was not significantly differentially expressed, regulatory relationship between 
SIVA1 and each one of 32 genes was significantly different between the GBM tumor tissue 
and normal tissue samples. This indicated that SIVA1 can act synergistically to influence the 
development of the GBM. SIVA1 is a pro-apoptotic protein. Function of SIVA1 is to promote 
DNA damage induced apoptosis and inhibit NF- B (Barkinge, et al., 2009). SIVA1 plays an 
important role in cell proliferation and death (Spinicelli, et al., 2002). It was reported that 
SIVA1 was involved in breast cancer (Chu, et al., 2005). GBAS named as Glioblastoma-
amplified sequence, was located in Chromosomal region 7p12, which contains the EGFR 
gene, and was reported to be co-amplified with EGFR in glioblastomas (Wang, et al., 1998). 
It was over expressed with p-value 51.01 10 in our expression data.CDK4 with degree (8) 
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and damage value (13) was up regulated in the GBM tumor tissue samples and significantly 
differentially expressed (P-value < 81.87 10 ). CDK4 was a member of the Ser/Thr protein 
kinase family and involved in Glioma pathway(Zhu and Parada, 2002). CDK4 was an 
oncogene and was reported to be associated with multiple tumors(Kim and Diehl, 2009). 
3.3 Network analysis of miRNA expressions  
3.3.1 Differential expression analysis 
To unravel the pattern of differential regulation of miRNA, expressions of 534 microRNAs 
including 470 human microRNAs were profiled in 240 tumor tissue samples and 10 normal 
tissue samples by Agilent 8 x 15K Human microRNA-specific microarray. A total of 149 
miRNAs were differentially expressed between the GBM tumor tissue and normal tissue 
samples which were identified by Wilcoxon rank-sum test (P-value for declaring 
significance after Bonferroni correction is 59.36 10 ). Of 149 differentially expressed 
miRNAs, 73 miRNAs were up-regulated and 76 down-regulated. Among them, 21, 81 and 
15 miRNAs were reported to be associated with the GBM, other cancers and other diseases, 
respectively, in the literatures(Jiang, et al., 2009) . 
 
 
Fig. 4. Gene interaction network. The largest connected gene interaction network consists of 
187 genes and 196 edges. Genes with different damage value were marked in different 
colors. 
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3.3.2 MiRNA co-expression network analysis 
Similar to genes, miRNAs are not isolated, instead they act together to perform biological 
functions. Initiation and progression of cancer are influenced not only by individual 
miRNAs, but also by the coordinated effect of many miRNAs. To understand how miRNAs 
regulate biological processes at a system level, we reconstruct miRNA co-expression 
network. The largest connected miRNA coexpression network with the average shortest 
path 10.75 and diameter 49 had 385 miRNAs and 451 edges (Figure 5). One main feature of 
this miRNA coexpression network is that mir-770-5p and mir-329 divided the whole 
network into three subnetworks: the left, the middle and the right subnetwork. The middle 
subnetwork was densely connected.   
 
 
 
Fig. 5. MiRNAs coexpression network. MiRNAs with damage value larger than 20 were 
highlighted in red and yellow, where red nodes denoted significantly differentially expressed 
miRNAs (p-value< 59.36 10 ) and yellow nodes denoted they were not significant. 
Similar to gene co-expression network, we used the damage value of a node as a robustness 
measure to rank the importance of a miRNA in miRNA co-expression network. We ranked 
all differentially expressed miRNAs in the largest miRNA co-expression network according 
to their damage values. There were 19 differentially expressed miRNAs with the largest 
damage values (>20) which we referred to as fragile miRNAs. Among the 19 fragile 
miRNAs, 16 miRNAs (14 miRNAs were over expressed in the GBM tissues) were in the left 
coexpression subnetwork, and 3 under expressed miRNAs were in the right coexpression 
subnetwork. The middle coexpression subnetwork contains no fragile miRNAs. Figure 5 
showed that miRNAs in the middle coexpression subnetwork were densely connected. The 
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middle coexpression network with large number of redundant miRNAs was highly robust 
in response to perturbation of external forces. From Figure 5, we can see that mir-487a, mir-
487b, mir-502 and mir-532 were the most important components in the miRNA co-
expression network. Removal of one of them would cause disconnection between the left 
part and right part of miRNA co-expression network and hence lead to dysfunction of the 
whole miRNA co-expression network. We observed that mir-487a and mi-487b were down-
regulated, and mir-502 and mir-532 were up-regulated in the GBM tissues. We searched 
miR2disease database (Jiang, et al., 2009) and found that 7 of the 19 miRNAs were associated 
to GBM/glioma/ neuroblastoma (mir-15b, mir-25, mir-93, mir-17-5p, mir-323, mir-106a, 
mir-92), 6 others were associated with cancer and neuro-diseases(mir-487b, mir-15a, mir-16, 
mir-106b, mir-218, mir-320). Take 
3.3.3 MiRNA interaction network analysis 
We also used MI to quantify interaction between miRNAs and MI-based statistic to detect 
pair-wise interaction between miRNAs. We assembled the interacted miRNAs into miRNA 
interaction network. Significant P-values for declaring an interaction between miRNAs were 
78.51 10  accounting for 1% proportion of total interactions. An assembled largest 
connected miRNA interaction network was shown in Figure 6. The network included 333 
miRNAs and 563 interactions. Its average shortest path length was 5.10281 and diameter 
was 17. 
 
 
Fig. 6. MiRNA interaction network. miRNAs with damage value larger than 4 were marked 
in blue and miRNAs with degree larger than 9 were marked in red. Significantly 
differentially expressed miRNAs (p-value< 59.36 10 ) were marked in black box. 
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To examine topological network properties of miRNA interaction networks, we also used 
the damage value and the degree of a node to identify cancer relevant miRNAs. Among all 
the miRNAs with either damage values greater than 4 or degrees greater than 9, miR-539 
was associated with autism spectrum disorder (ASD), a brain development disorder(Abu-
Elneel, et al., 2008). It was reported that mir-563 is involved in modulating tumors in 
variable microenvironments (Hebert, et al., 2007), miR-125a and miR-125b were indentified 
to control human neuroblastoma cell proliferation by repressing a common target gene 
NTRK3 (neurotrophic tyrosine kinase, receptor, type 3)(Laneve, et al., 2007). They were 
found to be down-modulated in primary neuroblastoma tumors and were under expressed 
with p-value 54.83 10 and 0.03 respectively in our dataset. 
3.4 miRNA target networks 
We compiled miRNA and mRNA expression data in 237 tumor tissue samples and 10 
normal tissue samples for 1,697 differentially expressed mRNAs and 149 differentially 
expressed miRNAs. This resulted in extremely complex miRNA target networks. We found 
3,953 matched miRNA-mRNA pairs for 127 differentially expressed miRNAs and 1, 089 
differentially expressed genes. Of the 3,953 target-pairs, 65 down-regulated miRNAs targets 
468 over expressed genes while 62 up-regulated miRNAs target 621 under expressed genes. 
A total of 14 experimentally verified targets of 7 miRNAs were listed in Table 7. Of 8 
miRNAs, 4 under expressed miRNAs (mir-124a, mir-29b, mir-29c and mir-33) function as 
tumor-suppressors and 4 over expressed miRNAs (mir-155, mir-16, mir-21 and mir-210) 
function as oncogenes. It has been reported that CTDSP1 was a validated target gene of mir-
124a (Karginov, et al., 2007), RTN4 and SLC25A22 was validated targets of mir-16 (Selbach, 
et al., 2008). mir-21 was found to be over expressed in multiple cancers and down regulated 
tumor suppressor genes: TPM1, PTEN, PDCD4 BASP1 and RTN4 in invasion and metastasis 
of cancer(Yang, et al., 2009).  BASP1 is a transcriptional cosuppressor for the Wilms' tumor 
suppressor protein WT1, thus it can regulate WT1 transcriptional activity (Carpenter, et al., 
2004). Nogo-A , one protein isoforms encoded by RTN4, had turned out to be a neuronal 
protein involved in diverse processes that go from axonal fasciculation to 
apoptosis(Mingorance, et al., 2004). Mir-155 targeted a regulator of apoptosis gene: LDOC1 
(Skalsky, et al., 2007). Up-regulation of miR-210 directly targeted gene EFNA3, which is 
crucial for endothelial cell response to hypoxia, affecting cell survival, migration, and 
differentiation (Fasanaro, et al., 2008). Mir-29c was reported to be under expressed in 
Nasopharyngeal Carcinomas and up-regulated genes COL4A1, COL4A2 and TDG 
(Sengupta, et al., 2008). COL4A1, COL4A2 were genes encoding extracellular matrix 
proteins, as we discussed previously, they played an important role in apoptosis, 
proliferation regulation and anticancer drug resistance (Sethi, et al., 1999) . COL4A2 was 
validated to be also targets of mir-29b in another research group (Li, et al., 2009). TDG was 
involved in DNA repair, a process frequently dysregulated in many cancers (Sengupta, et 
al., 2008). In mouse and human cells, miR-33 inhibits the expression of ABCA1, thereby 
attenuating cholesterol efflux to apolipoprotein A1 (Rayner, et al., 2010). It was also reported 
that the role of miR-33 controlling the hematopoietic stem cells self-renewal through p53 
may lead to the prevention and treatment of hematopoietic disorders (Herrera-Merchan, et 
al., 2010). 
The resulting miRNA target networks have several remarkable features. First, many 
important genes in the mRNA co-expression networks were targets of differentially 
expressed miRNAs. Top 17 genes with damage values greater than 19 in the gene co-
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expression network were negatively regulated by 34 differentially expressed miRNAs. All 
17 genes and many miRNAs were crucial components in the gene and miRNA 
 
 
 
 
* LDOC1 and RTN4 are tumor suppressor genes 
Table 7. Experimentally verified targets. 
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coexpression networks. Their altered expressions played an important role in tumorigenesis. 
Among them, overexpressed RBBP4 (P-value 81.8 10 ) with the largest damage value (37) 
in the table was negatively regulated by under expressed mir-29b (P-value 72.07 10 and 
mir-29c (P-value 73.66 10 ), underexpressed TRIM8 (P-value 63.77 10 ) with the damage 
value 29 was negatively regulated by overexpressed mir-629 (P-value 72.02 10 ),  
overexpressed TP53 ((P-value 71.40 10 ) with damage value 23 was negatively regulated 
by underexpressed mir-485-5p. RBBP4 has been implicated in chromatin remodeling and 
regulation of cell proliferation. It has been reported that RBBP4 is overexpressed in different 
human tumors, such as lung, liver and thyroid cancer, acute myelocytic leukemia, and acute 
lymphoblastic leukemia (Pacifico, et al., 2007). TRIM8 is thought of as a new tumor 
suppressor gene (Caligo, et al., 1997).  
Second, many genes targeted by critical components in miRNA co-expression network, 
played important roles in regulation of neural process and tumor genesis. To study the 
function of the top 19 differentially expressed miRNAs with the largest damage values, we 
constructed mRNA target network of these 19 miRNAs with 476 nodes and 1,128 arcs and 
174 edges shown in Figure 7A, where 5 underexpressed miRNAs negatively regulated 85 
over expressed genes and 14 overexpressed miRNA negatively regulated 372 
underexpressed genes, 1,128 arcs were miRNA-mRNA pairs, 15 edges connected co-
expressed miRNAs, and remaining 159 edges linked co-expressed genes. The genes with 
large damage value or related to cancer in the gene co expression network were highlighted 
and those gene were marked in the Figure 7A.  8 genes with the damage values greater than 
15 were regulated by 11 miRNAs with the damage values greater than 20. 14 of the15 cancer 
genes in Figure 7A were under-expressed FBXW7, GABRA1, MYT1L, NEFL, RTN1, 
SH3GL2, SNAP25, SV2B, SYN2, KIAA0774, VSNL1, NEFM, RIMS2, SYT1. These genes were 
regulated by 10 overexpressed miRNAs: mir-15b, mir-25, mir-16, mir-92, mir-15a, mir-320, 
mir-106b, mir-93, mir-106a, mir-17-5p, which were connected in the mRNA co-expression 
network (Figure 7B). They are involved in synaptic transmission process. Neuron 
communication occurs at the synapse via neurotransmitters. MYT1L (myelin transcription 
factor 1-like) regulates nervous system development. Both SYT1 and VSNL1 serve as Ca(2+) 
sensors in synaptic transmission(Maglott, et al., 2007). SNAP25 is a presynaptic plasma 
membrane protein and regulates neurotransmitter release. It is reported that SNAP25 is 
implicated in neuritogenesis in human neuroblastoma(Heraud, et al., 2008). GABRA1 
encodes a gamma-aminobutyric acid (GABA) receptor and GABA is the major inhibitory 
neurotransmitter in the mammalian brain. Both NEFL and NEFM are Neurofilaments. They 
play a role in intracellular transport to axons and dendrites. NRGN encodes a postsynaptic 
protein kinase substrate that binds calmodulin in the absence of calcium and is a direct 
target for thyroid hormone in human brain(Maglott, et al., 2007). FBXW7 serves as a 
negative regulator of oncoprotein and is a general tumor suppressor. It regulates cell 
differentiation and proliferation. It has been reported that FBXW7 is implied in various 
cancers including glioblastoma(Hagedorn, et al., 2007). Remaining genes that were involved 
in neuron communication include SLC6A15, SYN2, SV2B and RIMS2. SLC6A15 is a 
neurotransmitter transporter, SYN2 is a member of the synapsin gene family, SV2B is 
synaptic vesicle glycoprotein and RIMS2 regulates synaptic membrane exocytosis(Maglott, 
et al., 2007).  
Table 8 summarizes the major functions of target genes of miRNAs in Figure 7A where  
right-railed Fisher’s exact test were used to test for significantly enriched GO categories or 
pathways. Table 8 shows that the target genes of these miRNAs were mainly involved in 
cancer related signaling pathways and nerves systems process including synapse, 
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synaptic transmission, neurotransmitter transport, nervous system development and 
neurological system process. It is interesting to note that co-expressed mir-15a, mir-15b, 
mir-16, mir-25 and mir-92 were major miRNAs that targeted genes in both cancer related 
signaling pathways and nerves systems process.  
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Table 8. Function of target genes of 9 miRNAs. 
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Fig. 7. MiRNA target (sub)network. (A) mRNA target networks of the 19 miRNAs with 476 
nodes and 1,128 arcs and 174 edges, where 1128 arcs were miRNA-mRNA pairs, 15 edges 
connected coexpressed miRNAs, and remaining 159 edges linked coexpressed genes. The 
genes with large damage value or related to cancer in the co expression network genes were 
highlighted and those gene names were marked in the figure. (B) MiRNA target 
subnetwork. 7 genes with the damage values greater than 15 and 14 cancer related genes 
were regulated by 11 miRNAs with the damage values greater than 20. Those nodes and 
edges were extracted from Figure 7A mRNA target network. 
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Third, contribution of miRNAs to expression variation of some genes is very high. The 
proportion of expression variation of target gene explained by the linear influence of 
miRNA variation can be measured by the coefficient of determination ( 2R ). There were a 
total of 78 under-expressed genes with the coefficient of determination greater than 20% 
which were negatively regulated by 7 overexpressed miRNAs: mir-15a, mir-15b, mir-16, 
mir-25, mir-93, mir-106a and mir-106b. Surprisingly, up to 33% of expression variations of 
underexpressed gene GCC2 were explained by single overexpressed mir-25. Functional 
roles of GCC2 in cancer are unknown. The gene with the second largest coefficient of 
determination was CAMK2N1. Its 28% of expression variations were explained by 
overexpressed mir-106b. It was reported that CAMK2N1 is a candidate tumor suppressor 
(Wang, et al., 2008). Function of CAMK2N1 is to inhibit MEK/ERK activity and induce p27 
accumulation which negatively regulates cell-cycle progression. Reducing expression of 
CAMK2N1 will accelerate tumor growth. 26% of expression variation of CPEB1 that 
regulates synaptic plasticity and is implied in cancer development (Hansen, et al., 2009) and 
GRM1 that is involved in neurotransmitter in the central nervous system and implicated in 
Melanoma (Namkoong, et al., 2007) was explained by overexpressed mir-25 and mir-15b, 
respectively. Expressions of genes SYT1, SNAP25, GABRA1, VSNL1, MYT1L, SV2B, SYN2 
and SLC12A5 which were involved in synaptic transmission, were also largely regulated by 
miRNAs. 
Fourth, we observed that one miRNA may target multiple genes (up to 179 mRNAs) directly 
or indirectly, and multiple miRNAs (up to 9 miRNAs) can target a given gene. More than 
40% of expression variation of each of six genes (YWHAH, GABRA1, DYNC1I1, ERC2, 
PEX5L and CAMK2G) was explained by several miRNAs. Expressions of these genes were 
largely regulated by multiple differentially expressed miRNAs. YWHAH and GABRA1 are 
implied in neural diseases, and CAMK2G is involved in regulation of plasticity at 
glutamatergic synapses(Maglott, et al., 2007). Functions of other three genes are unknown. 
 
3.5 DNA methylation analysis  
To study how genes are regulated by DNA methylation in GBM, two methylation datasets: 
OMA-002 dataset and OMA-003 dataset were generated by TCGA project. OMA-002 dataset 
used the Illumina GoldenGate Methylation Cancer Panel 1 platform, which contains 1,505 
CpG loci selected from 813 genes. OMA-002 dataset included 239 GBM tumor tissue 
samples and 1 cell line, 228 of which were shared among the miRNA expression, gene 
expression datasets and thus used for Methylation-miRNA regression and Methylation-gene 
regression analysis. OMA-003 dataset used the Custom Illumina Goldengate Methylation 
Cancer Panel, which contains 1,489 gene promoters. 245 GBM tumor samples and 1 cell line 
were used for experimented, 234 of which were shared among the miRNA expression, gene 
expression datasets and used for Methylation-miRNA regression and Methylation-gene 
regression analysis.   
A total number of 341 genes were hypomethylated genes (average methylation ratio < 0.25 
and fold changes <0.5) in two datasets and 113 hypermethylated genes (average methylation 
ratio > 0.75 and fold changes > 1.5) in glioblastomas. For OMA002 dataset we averaged the 
methylation ratio for several probes in one gene. To investigate the effects of aberrant 
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methylation on gene expressions, we regressed gene expression on the methylation profile. 
We found that 120 hypermethylated genes negatively regulated 404 under expressed genes, 
and 41 hypomethylated genes negatively regulated 85 overexpressed genes. One methylated 
gene might influence expressions of up to 142 genes and multiple methylated genes (up to 
32) might regulate a given gene. Interestingly, we found that 56.3% of expression variation 
of  underexpressed tumor-suppressor gene BCL11B (P-value 71.75 10 )  is explained by 
hypermethylated gene HLA-DPB1 with Average methylation 0.9631 and fold change 7.4. 
We also found that a total of 24 hypermethylated genes that silenced expression of BCL11B 
(Table 9). These hypermethylated genes include PMP22, a major component of myelin in the 
peripheral nervous system, GPR116, involved in neuropeptide signaling pathway, LTA, 
involved in apoptosis.  Another gene with the largest coefficient of determination was 
ANXA5(P-value 63.07 10 ). ANXA5 binds to phosphatidylserine, which is one of the "eat 
me" signals at the surface of the apoptotic cell, thus involved in apoptosis and cancers 
(Boersma, et al., 2005). Up to 11 hypormethylated genes were negatively correlated with 
overexpression of ANXA5 (Table 9). 
Methylation also directly or indirectly regulates expression of miRNAs. We observed that 29 
underexpressed and 26 overexpressed miRNAs were directly or indirectly regulated by 82 
hypermethylated genes. One hypermethylated gene might significantly influence 
expressions of up to 25 miRNAs and multiple hypermethylated genes (up to 30) might 
influence expression of one miRNA. We also found that a total of 67 hypomethylated genes 
directly or indirectly induced expression variation of 38 down regulated and 23 up 
regulated miRNAs. One hypomethylated gene might influence expression of up to 25 
miRNAs and multiple hypomethylated genes (up to 22) might influence expression of one 
miRNA. 
A total of 542 underexpressed and 218 overexpressed genes were directly or indirectly 
regulated by 61 underexpressed and 62 overexpressed miRNAs, and 300 hypomethylated 
and 149 hypermethylated genes. In general, multiple miRNAs and methylated genes jointly 
contribute (in many cases, indirectly) to the variation of gene expressions. In many cases, 
both miRNAs and methylation repressed gene expression. However, surprisingly we 
observed that indirect effect of methylation on the regulation of gene expression was to 
increase gene expression rather than repressing gene expression. Functions of the many 
genes regulated by both miRNAs and methylation such as ANXA5, CACYBP, SLC17A7, 
SLC6A15, INA, SHANK2, PAK3, RIMS2, NBEA, VSNL1, GABRG2, PCLO, VAMP2, PLCB1, 
GRM7 and SNAP25 were involved in neuron communication and in nervous system. We 
also found that expressions of the cancer relevant genes TRIM8 (which has been tested for 
association with Glioblastoma), TP53, FGF13, ENC1, FBXW7, BCL2L2 were influenced by 
both miRNAs and methylation.  
 
Methylate
d gene 
Average 
Methylation 
Fold 
Changes 
Regu-
lated 
Regression 
coefficient  
P-value  
Coeffi-
cient  
HLA- 0.963075314 7.408272 BCL11B -2.01E+02 0.00E+00 5.63E-01 
TNF 0.954752441 5.967203 BCL11B -1.30E+02 2.22E-16 2.59E-01 
PMP22 0.912672293 40.56321 BCL11B -5.31E+01 6.94E-13 2.06E-01 
GPR116 0.945111576 7.270089 BCL11B -7.32E+01 6.84E-11 1.72E-01 
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Methylate
d gene 
Average 
Methylation 
Fold 
Changes 
Regu-
lated 
Regression 
coefficient  
P-value  
Coeffi-
cient  
FLJ25084 0.881295918 2.037678 BCL11B -6.56E+01 5.84E-11 1.69E-01 
EGF 0.870425384 2.451902 BCL11B -3.42E+01 2.84E-09 1.45E-01 
FCRLM1 0.819928571 46.85306 BCL11B -2.57E+01 4.03E-09 1.39E-01 
LTA 0.887046722 18.67467 BCL11B -5.02E+01 9.74E-09 1.36E-01 
TRPM5 0.84431311 2.447284 BCL11B -4.26E+01 8.54E-08 1.19E-01 
MPL 0.841936275 7.165415 BCL11B -3.40E+01 9.62E-08 1.19E-01 
BLK 0.954205021 42.40911 BCL11B -1.01E+02 5.84E-07 1.05E-01 
IL4 0.846998588 2.540996 BCL11B -3.64E+01 8.17E-07 1.03E-01 
HLA-DOB 0.886698047 39.4088 BCL11B -4.82E+01 9.44E-07 1.01E-01 
CD1D 0.955290456 3.746237 BCL11B -6.56E+01 1.09E-06 9.92E-02 
CLDN4 0.843246165 16.06183 BCL11B -3.49E+01 1.29E-06 9.87E-02 
CXCL9 0.76874477 2.520475 BCL11B -2.14E+01 1.36E-06 9.83E-02 
KISS1 0.925806122 4.571882 BCL11B -5.68E+01 1.59E-06 9.47E-02 
APOC2 0.88015625 1.614966 BCL11B -4.65E+01 1.33E-05 9.29E-02 
TNFRSF10 0.929268207 2.323171 BCL11B -4.22E+01 4.64E-06 8.92E-02 
C18orf2 0.755978723 4.142349 BCL11B -1.77E+01 1.24E-05 8.26E-02 
PLA2G2A 0.785191771 31.40767 BCL11B -2.25E+01 1.11E-05 8.21E-02 
EPHX1 0.900292887 1.809634 BCL11B -5.92E+01 1.16E-05 8.17E-02 
PLA2G2A 0.809780335 2.816627 BCL11B -2.74E+01 2.04E-05 7.74E-02 
KLK11 0.873908647 2.39427 BCL11B -3.44E+01 2.33E-05 7.63E-02 
MMP14 0.214993026 0.217165 ANXA5 -2.11E+03 0.00E+00 2.91E-01 
MST150 0.230010204 0.2788 ANXA5 -1.44E+03 1.09E-13 2.12E-01 
COL5A2 0.201823129 0.260417 ANXA5 -2.06E+03 1.55E-12 1.94E-01 
FRZB 0.152287308 0.491249 ANXA5 -1.62E+03 2.91E-11 1.78E-01 
PAX6 0.094173729 0.396521 ANXA5 -2.43E+03 3.41E-10 1.62E-01 
MMP14 0.165882148 0.402139 ANXA5 -2.45E+03 3.66E-09 1.43E-01 
DES 0.192259414 0.359363 ANXA5 -1.37E+03 1.66E-07 1.14E-01 
LOX 0.125711297 0.177058 ANXA5 -1.69E+03 2.65E-07 1.11E-01 
NEBL 0.06257483 0.161483 ANXA5 -2.18E+03 2.55E-06 9.12E-02 
SPARC 0.150543933 0.174039 ANXA5 -1.99E+03 6.49E-06 8.62E-02 
FGFR2 0.048397711 0.116621 ANXA5 -2.32E+03 1.94E-05 7.98E-02 
 
Table 9. 24 hypermethylated genes negatively regulated expression of gene BCL11B and 11 
hypomethylated genes regulated expression of gene ANXA5. 
3.6 Deciphering the path connecting mutations to gene and miRNA expression. 
To study function of somatic mutations and LOH and connect them with disease through 
gene expressions and miRNAs, we study their cis or trans regulatory effects on gene or 
miRNA expression traits. We applied the group regression method to expression profiles of 
12,042 genes and expression profiles of 470 human microRNAs in 169 tumor tissue samples 
from glioblastomas patients, which were shared among the gene expression, miRNA 
expression and mutation datasets. 
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Fig. 8. Somatic and LOH mutation eQTL network. (A) Somatic mutation eQTL network. A 
network that connects 14 genes with somatic mutations associated with GBM, their 
regulated mRNAs and miRNA expressions was shown. (B) LOH mutation eQTL network. A 
network that connects 11 genes with LOH associated with GBM, their regulated mRNAs 
and miRNA expressions was shown. 
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Table 10. Genes with somatic mutations regulate both mRNA and miRNA expressions, and 
formed triangle regulation cycles. 
We first studied cis regulatory effects of somatic and LOH mutations on mRNA or miRNA 
expression traits. For somatic mutation, we found four cis-eQTL: TP53, EGFR, NF1and 
PIK3C2G.  P-values for testing association of somatic mutations in TP53 , EGFR, NF1 and 
PIK3C2G with their expressions were 0.033, 0.019, 0.028 and 0.006, respectively. Fold 
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changes (defined as the ratio of their average expressions of the samples with somatic 
mutations over the average expressions of the samples without somatic mutations) for the 4 
genes were 1.10,1.73, 0.86,1.23, respectively. Although regression analysis did not show 
significant association of somatic mutations in BCL11A, FN1 and COL3A1 with their 
expressions due to very low frequencies of mutations, the fold changes were 1.45, 0.60 and 
0.20, respectively.  We still observed some regulatory effects of somatic mutations on these 
two genes. For LOH mutation, two cis-eQTL: NRAP and EGFR were detected with P-values 
0.030, 0.034 and fold change 0.90 and 2.32, respectively. Regression analysis did not show 
significant association of LOH mutations in gene CYP1B1 with their expressions, but the 
fold change were 0.48.   
Next we identified trans-regulatory effects of somatic and LOH mutations on mRNA or 
miRNA expression traits. The thresholds for declaring significant association of the set of 
somatic mutation and LOH in the gene with mRNA and miRNA expression after Bonferroni 
correction for multiple tests were 41.63 10  and 44.03 10 , respectively. A network that 
connects 14 genes with somatic mutations associated with GBM, and their regulated 
mRNAs and miRNA expressions was shown in Figure 8A. Somatic mutations in these 14 
genes were strongly correlated with expressions of 177 significantly differentially expressed 
genes, 45 of which were under-expressed and 132 were over-expressed in tumor tissue 
samples, a total of 262 trans gene eQTL were found. These mutations also significantly 
affected expressions of 23 miRNAs, 11 of which were underexpressed and 12 were 
overexpressed and a total of 26 trans miRNA eQTL were found. Remarkably, we found 5 
paths: (1) RB1 with association of somatic mutations with GBM regulated expressions of 
gene LAMP2 and mir-340, and mir-340 in turn targeted gene LAMP2; (2) DST with  
association of somatic mutations regulated expressions of both gene OTUB1 and mir-15b  
and mir-15b in turn targeted gene OTUB1; (3) FN1 with association of somatic mutations  
regulated expressions of both SSR2 and mir-125a and mir-125a in turn targeted gene SSR2; 
(4) FN1 with association of somatic mutations regulated expressions of both gene TDG and 
mir-125a and mir-125a in turn targeted gene TDG; and (5) TP53 with association of somatic 
mutations regulated expressions of both gene TP53 and mir-504 and mir-504 in turn 
targeted TP53 (Table 10). 
Similarly, Figure 8B showed a network that connects 11 genes with LOH mutations 
associated with GMB, their regulated mRNAs and miRNA expressions. These 11 genes with 
LOH as trans-eQTL affected 323 differentially expressed or interacted genes, 190 of which 
were underexpressed genes and 133 were overexpressed, a total of 409 trans gene-eQTL were 
found. The LOH also affected expressions of 19 miRNAs, 9 of which were underexpressed 
and 10 were overexpressed, 2 of them were differentially expressed and a total of 27 trans 
miRNA-eQTL were found.   
Sources for regulating gene expressions include DNA variations, miRNAs, and methylation. 
To provide a comprehensive view of how DNA variations, miRNA and methylation directly 
or indirectly regulate gene expression, we found a total of 87 underexpressed and 48 
overexpressed genes which were commonly regulated by 38 underexpressed and 28 
overexpressed miRNAs, 14 hypomethylated and 107 hypemethylated genes, and 9 
significant somatic mutation and 10 significant LOH mutation. Surprisingly, multiple 
genetic perturbations such as multiple genes with somatic mutations or LOH, multiple 
miRNAs and multiple methylation may directly or indirectly regulate expression of a single 
gene. For example, expression levels of BCL11b which is a haploinsufficient tumor 
suppressor gene were positively regulated by genes DST and BCL11A, with associated 
somatic mutations, and were negatively affected by over-expressed mir-155, mir-23a, mir-
92b and mir-30a-5p, and 24 hypermethylated genes. 
www.intechopen.com
 Integrated Network Analysis of Genetic and Epigenetic Factors in Glioblastoma Multiform 
 
233 
4. Discussion and conclusion 
Genetic and epigenetic alternations that are likely to cause tumor formation are often 
organized into complex biological networks. Genetic and epigenetic risk factors individually 
cannot fully explain initiation and progression of cancer. The purpose of this report is (1) to 
explore the possibility of integrating altered DNA variations, mRNA and miRNA 
expression variation, and methylation patterns into multi-level complex genetic and 
epigenetic networks that contribute to tumorigenesis; (2) decipher paths from somatic 
mutations and LOH to tumor formation through genetic and epigenetic networks; and (3) 
identify key genetic and epigenetic alternations causing tumor formation by network 
analysis.  
The approach developed here for integrating genetic and epigenetic alternations into 
molecular networks consists of three steps. The first step is to reconstruct single type 
molecular networks whose components are of the same type of molecules, either mRNAs or 
miRNAs. We reconstructed mRNA co-expression networks and miRNA co-expression 
networks for glioblastoma using partial correlation approach. The co-expression networks 
attempt to uncover the regulatory relationships among mRNAs or miRNAs. However, 
many examples show that the regulatory relationships may be changed when normal 
tissues become tumor tissues. To identify the alternated regulations we developed a novel 
mutual information-based statistic for testing interactions between mRNAs or miRNAs, 
which allow detecting differential regulations between tumor and normal tissues, and 
reconstructed mRNA and miRNA interaction networks. The second step is to identify 
miRNA target and reconstruct miRNA target networks that connect mRNA and miRNA co-
expression networks or mRNA and miRNA interaction networks. 
The third step is to decipher the paths from somatic and LOH mutations to tumor 
formation. The first issue is how to test association of somatic mutations or LOH with 
glioblastoma. We developed a group association test that is based on population genetics for 
assessing association of somatic mutations and LOH with cancer. We identified 14 genes 
harboring somatic mutations associated with glioblastoma and 11 genes harboring LOH 
associated with glioblastoma. The second issue is how to uncover the components of mRNA 
or miRNA co-expression networks and interaction networks that respond to somatic 
mutations and LOH associated with glioblastoma. Traditionally, when alleles are common, 
these components are identified by mapping cis-eQTL or trans-eQTL. However, when alleles 
are rare, these components are hard to find by individually mapping cis-eQTL or trans-
eQTL.  The approach developed here is to extend group tests for a qualitative trait to a 
quantitative trait. The components that respond to perturbation of rare somatic genetic 
variants were identified by regressing the expression of an mRNA or an miRNA on the 
number of all mutated alleles across the gene. We discovered large comprehensive genetic 
and epigenetic networks that connect genes harboring associated mutations or LOH, 
mRNAs and miRNAs. Interestingly, we found five triangle cycles in the networks which 
indicated that significantly associated somatic mutations or LOH regulated   both 
differentially expressed mRNA and miRNA and the miRNA in turn also affected expression 
levels of the mRNA. The approach presented here has two remarkable features. First, it 
offered a powerful tool for differentiating driver mutations from passenger mutations. 
Second, it provides functional information on how somatic or LOH mutations lead to 
tumorigenesis through complex genetic and epigenetic networks. Similar to mutations, 
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methylation is another source for causing tumorigenesis. By regressing expression levels of 
mRNA or miRNA on methylation level, we can incorporate methylation into network. 
Finally we identified large genetic and epigenetic networks including associated mutations, 
LOH, methylation, differentially expressed mRNAs and miRNAs to explain how mutations 
and methylation cause tumorigenesis through molecular networks.  
Our studies support the hypothesis that cancer may be the emergent properties of large 
genetic and epigenetic networks that are highly interconnected. Genetic, epigenetic and 
environmental stimuli can be viewed as random attacks to genetic and epigenetic networks. 
Topological properties of the genetic and epigenetic networks are closely related to the 
function of cells. Cancer arises from the failure of genetic and epigenetic networks to 
respond to attacks. In other words, the attacked networks are unable to return to their 
normal states and remain functional in the face of random perturbations. We suspect that 
key components of network contributing to the robustness of the network also play an 
important role in the function of cells. We modeled over- or under-expression of mRNA and 
miRNA, methylation, and genetic alternation as deletion of a node in the network which 
will cause dynamical changes in the network and used a damage value of the node to 
measure its contribution to the robustness of the network. We found the several cancers 
related genes such as TP53 have large damage values in the genetic and epigenetic 
networks. These key components in the network may serve as therapeutic intervention 
points.  
Our results are preliminary. Although network analysis may have the potential to unravel 
the mechanism of tumor initiation and progression, the presented network structures and 
their properties in this report may depend on sample size. Whether the structures of our 
reconstructed genetic and epigenetic network can be replicated in other samples or not is a 
key to the success of network analysis in cancer studies.  
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